Neuphoria Therapeutics
NEUP
$4.32 1.16%
Exchange: NASDAQ | Sector: Healthcare | Industry: Medical Pharmaceuticals
Q1 2026
Published: Nov 14, 2025

Earnings Highlights

  • EPS of $-4.41 decreased by 22% from previous year
  • Net income of -9.91M
  • "Transcript not provided." - N/A
NEUP
Company NEUP

Executive Summary

Neuphoria Therapeutics, a clinical-stage biotechnology company focused on neuropsychiatric disorders, reported a non-revenue QQ1 2026 quarter consistent with a pre-commercial biotech model. The quarter shows an operating loss of $5.65 million and a net loss of $9.91 million (EPS -$4.41), driven predominantly by R&D and general and administrative expenditures. Cash burn from operations was $3.79 million, offset by $3.25 million of net financing proceeds, resulting in a net cash decrease of $0.56 million for the quarter. Ending cash was approximately $13.73 million, and the company remains free of long-term debt, with a net cash position of about $13.56 million after considering other balance sheet components.

Key Performance Indicators

Operating Income
Decreasing
-5.65M
QoQ: -147.20% | YoY: -136.12%
Net Income
Decreasing
-9.91M
QoQ: -187.96% | YoY: -256.61%
EPS
Decreasing
-4.41
QoQ: -9 268.40% | YoY: -22 631.96%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 0.00 -4.41 +0.0% View
Q3 2024 15.00 0.05 +0.0% View
Q2 2024 0.66 -0.01 +0.0% View
Q1 2024 0.00 0.00 +0.0% View
Q3 2023 0.00 -0.02 +0.0% View